Trikafta’s U.S. list price is over $322,000 a year. That is nearly 60 times the annual salary of a minimum wage earner in Turkey, where the government wanted to import a generic version made in Argentina. Vertex sued and blocked it.
Vertex has brought in $17 billion from Trikafta since 2019. An analysis by researchers in Britain found that a year’s supply of the drug could be manufactured for just $5,700.
The company says it is working to increase access to the drug globally.